SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

PU-H71 (hydrate)

Item No. 11450

CAS Registry No.:	1202865-65-3
Formal Name:	6-amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-9H-purine-9-propanamine, hydrate
MF:	$C_{18}H_{21}IN_6O_2S \bullet XH_2O$
FW:	512.4
Purity:	≥98%
UV/Vis.:	λ_{max}: 219, 285, 349 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PU-H71 (hydrate) is supplied as a crystalline solid. A stock solution may be made by dissolving the PU-H71 (hydrate) in the solvent of choice. PU-H71 (hydrate) is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of PU-H71 (hydrate) in these solvents is approximately 10 mg/ml.

PU-H71 (hydrate) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, PU-H71 (hydrate) should first be dissolved in DMF and then diluted with the aqueous buffer of choice. PU-H71 (hydrate) has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

PU-H71 is an inhibitor of heat shock protein 90 (Hsp90; IC_{50} = 16.1 nM in a fluorescence polarization assay).[1] It induces HER2 degradation *via* disrupting Hsp90-HER2 interactions and decreases growth in SK-BR-3 breast cancer cells (IC_{50} = 50 nM for both). PU-H71 (1 µM) decreases viability of MM.1S and dexamethasone-resistant MM.1R multiple myeloma cells. It induces cell cycle arrest at the G_1/S phase in MM.1R cells when used at a concentration of 100 nM.[2] PU-H71 (75 mg/kg every other day) decreases tumor volume in MDA-MB-231 and HCC1806 breast cancer xenograft mouse models.[3]

References

1. He, H., Zatorska, D., Kim, J., *et al*. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. *J. Med. Chem.* **49(1)**, 381-390 (2006).
2. Usmani, S.Z., Bona, R.D., Chiosis, G., *et al*. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1. *J. Hematol. Oncol.* **3(40)**, 1-8 (2010).
3. Caldas-Lopes, E., Cerchietti, L., Ahn, J.H., *et al*. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. *Proc. Natl. Acad. Sci. USA* **106(20)**, 8368-8373 (2009).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM